Alogliptin (NESINA), a dipeptidyl peptidase IV (DPP-4) inhibitor, was approved by the FDA on January 25, 2013 to improve blood sugar control in adults with type 2 diabetes. This drug had been ...

The following is a summary of "Adherence and persistence among people with type 2 diabetes newly initiating oral semaglutide ...

For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a lower risk for venous thromboembolism (VTE).

A total of 20,146 patients with nephrolithiasis and type 2 diabetes, including those with gout at baseline, initiated an SGLT ...

For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with ...